Eli Lilly's Options Frenzy: What You Need to Know - Eli Lilly (NYSE:LLY)

Group 1: Market Sentiment and Options Activity - Deep-pocketed investors have adopted a bullish approach towards Eli Lilly, indicating potential significant developments ahead [1] - Benzinga's options scanner highlighted 39 extraordinary options activities for Eli Lilly, with 35% of investors leaning bullish and 35% bearish [2] - The total volume of notable options includes 11 puts totaling $545,137 and 28 calls amounting to $3,038,945 [2] Group 2: Price Predictions and Trading Trends - Big players are eyeing a price range from $550.0 to $1100.0 for Eli Lilly over the past quarter [3] - Volume and open interest trends provide insights into liquidity and interest levels for Eli Lilly's options at specific strike prices [4] Group 3: Current Market Status and Analyst Opinions - Eli Lilly's current market status shows an average target price of $1118.8 from 5 industry analysts [10] - Analysts from various firms have differing ratings and target prices, with JP Morgan at $1150, Freedom Capital Markets at $950, Leerink Partners at $1104, Morgan Stanley at $1290, and BMO Capital at $1100 [11] Group 4: Company Overview - Eli Lilly focuses on neuroscience, cardiometabolic, cancer, and immunology, with key products including Verzenio, Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, Humulin, Taltz, and Olumiant [9]